NASDAQ:ACXP Stock Quote
Acurx Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel antimicrobial therapies to combat bacterial infections, particularly those caused by antibiotic-resistant pathogens
The company is engaged in research and development of innovative drug candidates that address critical unmet medical needs in the treatment of serious infections. With a commitment to advancing therapeutic options, Acurx aims to improve patient outcomes through its proprietary drug formulations and scientific expertise. The company's efforts are geared toward not only treating existing infections but also preventing the spread of multidrug-resistant bacteria in healthcare settings.
Frequently Asked Questions
How can I learn more about Acurx Pharmaceuticals, Inc.?
To learn more about Acurx Pharmaceuticals, Inc., interested individuals can visit the company’s official website, review corporate filings with the SEC, and follow press releases and news updates related to their research and development activities.
How can investors obtain shares of Acurx Pharmaceuticals, Inc.?
Investors can obtain shares of Acurx Pharmaceuticals, Inc. by purchasing them through a brokerage account that offers NASDAQ stocks, either via direct purchase of shares or investment in funds that include ACXP in their portfolios.
How does Acurx plan to address antibiotic resistance?
Acurx plans to address antibiotic resistance through the development of novel antibacterial agents that target specific bacterial mechanisms, thereby preserving the effectiveness of current antibiotics and providing new treatment options for resistant infections.
How is Acurx funded?
Acurx is funded through a combination of public and private investment, including funding from venture capital, public stock offerings, and grants aimed at specific research projects in antibiotic development.
Is Acurx a publicly traded company?
Yes, Acurx Pharmaceuticals, Inc. is a publicly traded company listed on the NASDAQ under the ticker symbol ACXP, allowing public investors to buy and sell its shares.
What are Acurx's growth prospects?
Acurx's growth prospects are tied to the successful development and commercialization of its product candidates, particularly in the growing market of antibiotic therapies. With increasing antibiotic resistance, the need for effective treatments is paramount.
What are the risks associated with investing in Acurx Pharmaceuticals, Inc.?
As a clinical-stage biopharmaceutical company, investing in Acurx Pharmaceuticals, Inc. carries risks typical of the biotech sector, including the failure to achieve clinical trial results, regulatory challenges, and competition from existing and emerging therapies.
What does Acurx Pharmaceuticals, Inc. do?
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing antibacterial therapies. Its primary research aims to address the growing problem of antibiotic resistance through innovative drug design, specifically targeting serious infections.
What is Acurx's lead product candidate?
Acurx's lead product candidate is called Acurx-001, which is designed to treat serious infections caused by antibiotic-resistant bacteria. It has shown promise in initial clinical trials.
What is antibiotic resistance?
Antibiotic resistance occurs when bacteria evolve and develop the ability to defeat drugs that were once effective in treating infections they cause. This poses a significant challenge to public health worldwide.
What is the mission of Acurx Pharmaceuticals, Inc.?
The mission of Acurx Pharmaceuticals, Inc. is to develop innovative therapies specifically targeting antibiotic-resistant infections, thereby improving the treatment options available for patients suffering from these serious conditions.
What is the significance of antibiotic discovery and innovation?
Antibiotic discovery and innovation are vital for public health as new antibiotics are essential for treating infections, particularly given the rise of resistant bacterial strains that challenge existing therapeutic options.
What is the ticker symbol for Acurx Pharmaceuticals, Inc.?
The ticker symbol for Acurx Pharmaceuticals, Inc. is ACXP, and it is traded on the NASDAQ stock exchange.
What partnerships does Acurx have?
Acurx Pharmaceuticals, Inc. actively seeks collaborations and partnerships with research institutions, pharmaceutical companies, and investors to enhance its research capabilities, advance clinical trials, and bring its products to market.
What regulatory bodies oversee Acurx's clinical trials?
Acurx's clinical trials are overseen by the U.S. Food and Drug Administration (FDA), which ensures that trials meet strict guidelines for safety and efficacy during drug development.
What type of clinical trials has Acurx conducted?
Acurx has conducted Phase 1 clinical trials for its lead product candidate, Acurx-001, which assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers.
When was Acurx Pharmaceuticals, Inc. founded?
Acurx Pharmaceuticals, Inc. was founded in 2015, embarking on a mission to develop new treatments for bacterial infections and combat antibiotic resistance.
Where is Acurx Pharmaceuticals, Inc. headquartered?
Acurx Pharmaceuticals, Inc. is headquartered in New York City, New York, where it conducts its research and development activities.
Who are the key members of Acurx's management team?
Acurx's management team is composed of experienced professionals with backgrounds in pharmaceuticals, healthcare, and biotechnology. The leadership often includes experts in drug development, commercialization, and regulatory approval.
What is the current price of Acurx Pharmaceuticals, Inc. - Common Stock?
The current price of Acurx Pharmaceuticals, Inc. - Common Stock is 0.3570
When was Acurx Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Acurx Pharmaceuticals, Inc. - Common Stock was at 2:03 pm EDT on April 2nd, 2025